Format

Send to

Choose Destination
See comment in PubMed Commons below
Gynecol Obstet Fertil. 2012 Apr;40(4):241-54. doi: 10.1016/j.gyobfe.2012.02.015. Epub 2012 Mar 30.

[Management of hot flushes for breast cancer survivors].

[Article in French]

Author information

1
Service de chirurgie gynécologique et médecine de la reproduction, CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. gboutetpourgof@yahoo.fr

Abstract

Hot flushes experienced by breast cancer survivors present specific issues due to their frequency, severity and difficulty to treat. After an evaluation of her symptoms and expression of her expectations and requests, each patient will be provided a clear, synthetic, comprehensible, supported and prioritized view of all treatment options. Any prescribed treatment will be a shared medical decision making. An algorithm of treatment propositions, documented by evidence-based medicine, is proposed. As randomized trials show that placebo-induced reduction of hot flushes frequency represents to 25 to 75%, non-pharmacological approaches selected by the patient should be preferred at first, to the exception however of phytoestrogens. The first-line treatment for severe hot flushes should be, depending on each specific context, venlafaxine, paroxetine or gabapentine. In case of inefficiency, treatments of second- and third-line will be proposed. Prescription of progestin or of a menopausal hormone therapy should remain exceptional and limited to cases where all other treatments failed, after obtaining the patient's informed consent following exhaustive information. Indications of stellate ganglion block remain to be defined.

PMID:
22464746
DOI:
10.1016/j.gyobfe.2012.02.015
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center